Rock Springs Capital is a Baltimore, Maryland based hedge fund established in 2013 that specializes in the healthcare and biotechnology sector. The firm is a long/short equity fund.
Rock Springs Capital advisory activities include management services to security portfolios and portfolio management for businesses or institutional clients.
Rock Springs Capital has made investments in Inozyme, Fusion Pharmaceutical, Imara, Vedanta Biosciences, Akero Therapeutics, Aprea, Mirum Pharmaceuticals and Galera Therapeutics.
Their exits include BeiGene, Invitae, Galera Therapeutics, Spark Therapeutics, Adaptive Biotechnologies, Ra Pharmaceuticals, AveXis, Menlo Therapeutics, Kaleido BioSciences, ZAI Lab, Ardelyx and Synlogic.
Rock Springs Capital has raised a total of $1.5 billion across 2 funds, their latest being Rock Springs Capital Fund. This fund was announced on October 5, 2017 and raised a total of $1.1 billion. They announced their Rock Springs Capital Offshore Fund on September 11, 2017 with a raised total of $395.9 million.
A biopharmaceutical company that develops treatments for multi-drug resistant (MDR) bacterial infection
Biotechnology company using alpha particle emitting medical isotopes in targeted radiotherapy for cancer.
A biotechnology company that develops medicines based on live bacterial consortia that can colonize the human intestine.
A company developing therapeutics for the treatment of cancer
A company focused on development and manufacture of products for endovascular aortic repair
Spark Therapeutics is a Philadelphia County, Pennsylvania-based company.
Mirum Pharmaceuticals is a Menlo Park, California-based company.
Coherus BioSciences is a Redwood City, California-based company.
Homology Medicines is a Bedford, Massachusetts-based company.
Imara is a Cambridge, Massachusetts-based company.
Menlo Therapeutics is a Redwood City, California-based company.
Akero Therapeutics is a Cambridge, Massachusetts-based company.